Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Non-Current Assets of $1.2 million for Q1 2026, up 891.52% year-over-year from $116564.0 in Q1 2025, and up 5.54% quarter-over-quarter from $1.1 million in Q4 2025.
Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Non-Current Assets for 6 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 891.52% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $3.4 million (up 398.23% YoY), while the FY2025 annual figure was $1.1 million, up 637.27% from the prior year.
- Non-Current Assets advanced to $1.2 million in Q1 2026 per IKT's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.2 million in Q1 2026 and bottomed at $43089.0 in Q2 2022.
- Historically, Non-Current Assets has averaged $439413.5 across 5 years, with a median of $312814.5 in 2023.
- Annual changes were most pronounced in 2025 — Non-Current Assets tumbled 73.84% — and 2026, when it surged 891.52%.
- Inhibikase Therapeutics' Non-Current Assets stood at $565175.0 in 2022, then tumbled by 47.7% to $295599.0 in 2023, then slumped by 49.75% to $148537.0 in 2024, then jumped by 637.27% to $1.1 million in 2025, then advanced by 5.54% to $1.2 million in 2026.
- Business Quant data shows IKT's Non-Current Assets at $1.2 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.24 Mn |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 58,605.00 |
| Mar 31, 2025 | 116,564.00 |
| Dec 31, 2024 | 148,537.00 |
| Sep 30, 2024 | 186,772.00 |
| Jun 30, 2024 | 223,997.00 |
| Mar 31, 2024 | 260,264.00 |
| Dec 31, 2023 | 295,599.00 |
| Sep 30, 2023 | 330,030.00 |
| Jun 30, 2023 | 363,615.00 |
| Mar 31, 2023 | 534,752.00 |
| Dec 31, 2022 | 565,175.00 |
| Sep 30, 2022 | 594,824.00 |
| Jun 30, 2022 | 43,089.00 |
| Mar 31, 2021 | 2,783.00 |